NCT02566226View on ClinicalTrials.gov

Impact of Intrathecal Morphine on Sleep Apnea Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Sleep Apnea Syndromes
Interventions
DRUG

Bupivacaine with normal saline

Isobaric bupivacaine 15 mg + normal saline 0.5 cc

DRUG

Bupivacaine with intrathecal morphine

Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg

Trial Locations (1)

Unknown

Lausanne University Hospital, Lausanne

All Listed Sponsors
lead

Centre Hospitalier Universitaire Vaudois

OTHER

NCT02566226 - Impact of Intrathecal Morphine on Sleep Apnea Syndrome | Biotech Hunter | Biotech Hunter